GUARNERI, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 12478
EU - Europa 970
AS - Asia 632
SA - Sud America 10
OC - Oceania 4
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14096
Nazione #
US - Stati Uniti d'America 12455
CN - Cina 494
IT - Italia 343
FI - Finlandia 237
SE - Svezia 230
VN - Vietnam 103
DE - Germania 53
GB - Regno Unito 38
IE - Irlanda 27
IN - India 24
CA - Canada 23
UA - Ucraina 10
BR - Brasile 9
FR - Francia 7
NL - Olanda 7
BE - Belgio 6
ES - Italia 4
JP - Giappone 4
AU - Australia 2
CH - Svizzera 2
NZ - Nuova Zelanda 2
PH - Filippine 2
SI - Slovenia 2
AL - Albania 1
BD - Bangladesh 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EU - Europa 1
IR - Iran 1
KR - Corea 1
KZ - Kazakistan 1
MY - Malesia 1
PL - Polonia 1
SC - Seychelles 1
Totale 14096
Città #
Fairfield 2653
Woodbridge 1464
Houston 1339
Chandler 1083
Ashburn 982
Ann Arbor 979
Cambridge 884
Seattle 880
Wilmington 779
San Diego 266
Medford 251
Princeton 251
Des Moines 208
Padova 167
Nanjing 117
Roxbury 109
Dong Ket 102
Helsinki 102
Boardman 89
Beijing 88
Shenyang 42
Nanchang 33
Guangzhou 30
Hebei 29
Dublin 27
Jinan 27
Tianjin 26
Jiaxing 22
Changsha 18
Norwalk 18
Ottawa 17
Falls Church 16
Milan 14
Venice 12
London 10
Zhengzhou 10
Kharkiv 9
Haikou 7
Redwood City 7
Selvazzano Dentro 7
Brussels 6
Hefei 6
Pignone 6
Rome 6
Rubano 6
Ningbo 5
Piove Di Sacco 5
São Paulo 5
Bologna 4
Borås 4
Chicago 4
Enterprise 4
Lanzhou 4
Taiyuan 4
Avezzano 3
Hangzhou 3
Orange 3
San Francisco 3
Shanghai 3
Taizhou 3
Toronto 3
Verona 3
Bergamo 2
Caserta 2
Castelfranco Veneto 2
Cesena 2
Chongqing 2
Clermont-Ferrand 2
Duncan 2
Indiana 2
Kunming 2
Naples 2
Paris 2
Redmond 2
Rockville 2
Tokyo 2
Turin 2
Xian 2
Almaty 1
Amsterdam 1
Auckland 1
Baotou 1
Brentford 1
Cagliari 1
Caloocan City 1
Candiolo 1
Casier 1
Colognola 1
Costabissara 1
Delhi 1
Dunoon 1
Edogawa 1
Enschede 1
Florence 1
Fuzhou 1
Gaithersburg 1
Geislingen an der Steige 1
Gubbio 1
Hanoi 1
Hanover 1
Totale 13321
Nome #
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 167
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 160
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 127
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 127
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 122
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 121
In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens 120
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 119
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 117
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 116
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 115
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 113
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 111
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 111
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 111
Immune characterization of breast cancer metastases: Prognostic implications 110
Escalation and de-escalation in HER2 positive early breast cancer 108
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 107
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 107
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 106
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 105
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: Individual patient data meta-analysis 104
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 104
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 104
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 101
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 99
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 99
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? 96
Olaparib for the treatment of breast cancer 95
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 94
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 94
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 93
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 92
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 90
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 90
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 89
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study 87
Fat grafting for breast cancer patients: From basic science to clinical studies 86
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 85
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 85
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. 85
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 84
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 84
Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies 81
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 81
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. 79
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. 79
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. 78
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents 78
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 78
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 77
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 77
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 77
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 76
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 76
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 76
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 75
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer 75
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 75
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis 74
Clinical utility of measuring circulating tumor cells in metastatic breast cancer 74
Controversies of chemotherapy for the treatment of metastatic breast cancer. 74
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 74
Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas 74
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 74
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 74
Trastuzumab containing regimens for early breast cancer. 74
The curability of breast cancer and the treatment of advanced disease 73
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial 73
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer 73
PIK3CA: a Target or a Marker in Breast Cancers 72
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 71
The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View 70
Timing for starting second line therapy in recurrent ovarian cancer. 70
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 69
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 69
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 69
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. 68
Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. 68
Achievements and unmet needs in the management of advanced ovarian cancer 68
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma 68
HER2-Positive Early Breast Cancer 68
Biomarkers predicting clinical benefit: fact or fiction? 67
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 67
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 67
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 67
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 67
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study 67
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) 67
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 66
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. 66
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 65
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 65
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience 65
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 64
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 64
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 64
Trastuzumab-containing regimens for metastatic breast cancer 64
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. 63
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. 63
Totale 8597
Categoria #
all - tutte 27058
article - articoli 26406
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 451
Totale 53915


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018109 0000 00 015 00940
2018/20191255 04511 82 3105 10237481389
2019/20203177 4267690466 325192 287330 396293183113
2020/20212994 9316291143 135549 296196 372368271318
2021/20223568 155396432199 306246 284273 215116263683
2022/20231768 483225109283 321250 5245 0000
Totale 14390